<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(21)</volume><submitter>Zhang H</submitter><pubmed_abstract>A novel theranostic prodrug was designed and synthesized by conjugating a naphthalimide derivative with vitamin D&lt;sub>2&lt;/sub> &lt;i>via&lt;/i> a disulfide linker. The prodrug featured a highly selective detection process for glutathione (GSH) and showed a red-shifted fluorescence within 30 min. Notably, it also exhibited antitumor activity similar to vitamin D&lt;sub>2&lt;/sub> and could be monitored by cellular imaging.</pubmed_abstract><journal>RSC advances</journal><pagination>11419-11423</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9079131</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A novel glutathione-triggered theranostic prodrug for anticancer and imaging in living cells.</pubmed_title><pmcid>PMC9079131</pmcid><pubmed_authors>Fang Z</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel glutathione-triggered theranostic prodrug for anticancer and imaging in living cells.</name><description>A novel theranostic prodrug was designed and synthesized by conjugating a naphthalimide derivative with vitamin D&lt;sub>2&lt;/sub> &lt;i>via&lt;/i> a disulfide linker. The prodrug featured a highly selective detection process for glutathione (GSH) and showed a red-shifted fluorescence within 30 min. Notably, it also exhibited antitumor activity similar to vitamin D&lt;sub>2&lt;/sub> and could be monitored by cellular imaging.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Mar</publication><modification>2025-04-18T14:14:08.216Z</modification><creation>2025-02-19T03:25:28.674Z</creation></dates><accession>S-EPMC9079131</accession><cross_references><pubmed>35542771</pubmed><doi>10.1039/c8ra00271a</doi></cross_references></HashMap>